Astrazeneca plc announce an interim dividend increased 3% to $1.03 (76.7 pence, 9.81 SEK)
Other financial highlights include:
* Total Revenue up 11% to $28,045m, driven by double-digit growth in Oncology and BioPharmaceuticals
* Growth in Total Revenue across all major geographic regions
* Core Operating profit increased 13%
* Core EPS increased 17% to $4.66
* 12 positive Phase III readouts and 19 approvals in major regions
